Αρχική World News ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk Stage...

ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk Stage II Colon Cancer

The Asian researchers reported on 25 October 2020 in the Annals of Oncology that 3-month of combination therapy for adjuvant treatment of high-risk stage II colon cancer resulted with significantly less grade ≥2 peripheral sensory neuropathy (PSN) than the 6-month regimen. The 3-month regimen did not affect the 3-year disease-free survival (DFS) rate. The ACHIEVE-2 (Adjuvant Chemotherapy for colon cancer with HIgh EVidencE in high-risk stage 2) researchers concluded that a 3-month course of adjuvant CAPOX can be an option for high-risk stage II colon cancer.

Oxaliplatin-based adjuvant chemotherapy is considered an option for patients with high-risk stage II colon cancer. However, many patients develop PSN during the 6 months of oxaliplatin-based adjuvant therapy, leading to treatment modification or discontinuation. The incidence of long-lasting PSN is significantly lower with 3-month therapy than with 6-month therapy, and significantly lower with CAPOX than with mFOLFOX6.

The phase III ACHIEVE-2 study of 3 versus 6 months of mFOLFOX6/CAPOX adjuvant therapy for high-risk stage II colon cancer was conducted to assess the potential implications in reducing the adjuvant therapy duration to 3 months for Asian patients. One of the key objectives of the ACHIEVE-2 study was to provide data pertaining to Asian patients for the International Duration Evaluation of Adjuvant (IDEA) chemotherapy pooled analysis to investigate the non-inferiority of 3 versus 6 months of FOLFOX or CAPOX adjuvant chemotherapy.

The IDEA pooled analysis for high-risk stage II colorectal cancer also collected data from three other phase III trials (SCOT [UK, Denmark, Spain, Sweden, Australia, and New Zealand], TOSCA [Italy], and HORG [Greece]) to compare the therapeutic effect (non-inferiority) of 3 months versus 6 months of adjuvant treatment in patients with high-risk stage II colon cancer worldwide.

The ACHIEVE-2 was open-label, multicentre, randomised phase III study, a prospective pooled analysis conducted to investigate the non-inferiority of 3 versus 6 months of adjuvant oxaliplatin-based chemotherapy in stage II disease. From February 2014 to January 2017, 525 Asian patients with high-risk stage II colon cancer were randomly assigned to 3- and 6-month treatment arms. The treatment consisted of either mFOLFOX6 or CAPOX. The primary endpoint was DFS. The secondary endpoints were treatment compliance and safety.

Of the 525 randomized patients, 11 were not treated. Among the 514 participating patients (255 in the 3-month arm; 259 in the 6-month arm), 432 (84%) received CAPOX. In total, 184 (36%) presented T4 as a high-risk factor for recurrence.

The 3-year DFS rate was 88.2% in the 3-month arm and 87.9% in the 6-month arm (hazard ratio [HR] 1.12; 95% confidence interval [CI] 0.67–1.87). With CAPOX, the 3-year DFS rate was 88.2% in the 3-month arm and 88.4% in the 6-month arm (HR 1.13; 95% CI 0.65–1.96).

The discontinuation rate in the 3- and 6-month arms was 10% and 31% for mFOLFOX6 (p = 0.0193), and 15% and 35% for CAPOX (p < 0.0001), respectively.

The incidence of grade ≥2 PSN was significantly lower in the 3-month arm than in the 6-month arm, 16% and 43%, respectively (p < 0.0001).

The authors concluded that a shorter duration of oxaliplatin-based adjuvant chemotherapy significantly reduced grade ≥2 PSN, and it did not compromise the DFS. However, this study was conducted as a part of the IDEA Collaboration trials and did not have the statistical power to independently determine the optimised adjuvant chemotherapy duration.

Nevertheless, the data suggested that patients with high-risk stage II colon cancer, especially patients with non-T4 and high-risk stage II colon cancer, receiving oxaliplatin-based adjuvant chemotherapy can be considered for 3 months of CAPOX therapy as a treatment option with favourable risk–benefit balance.


Yamazaki K, Yamanaka T, Shiozawa M, et al. Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon Cancer: The Randomized Phase 3 ACHIEVE-2 Trial. Annals of Oncology; Published online 25 October 2020. DOI: https://doi.org/10.1016/j.annonc.2020.10.480.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Making Important Decisions During Cancer: A Survivor’s Story

Bethany Hart lives with her husband Kevin, sons, and 3 dogs in the suburbs of Indianapolis, Indiana. She is a survivor of small cell neuroendocrine cervical cancer....

Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer

October 26, 2021, by NCI Staff Atezolizumab (Tecentriq) is approved as an additional treatment for some patients with stage II to IIIA (pictured) non-small cell...

Cure Probability Models for Evaluation of Patients with a Previous Cancer Diagnosis for Solid Organ Transplantation

Findings from a first study that applied a formal statistical framework to inform the evaluation of transplant candidates with a previous cancer diagnosis were...

Teacher Reads To Students One Day After Having Brain Surgery

Meucci - who had her surgery on a Wednesday - was going live from her intensive care unit hospital room that very next Thursday...

6 things you need to know about cervical screening

This article was originally published in 2017 during Cervical Screening Awareness Week. It has now been reviewed and updated. Cervical screening, also known as the...

EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan

On 14 October 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...